Kendall Capital Management Biogen Inc. Transaction History

Kendall Capital Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$194.69 - $268.46 $146,017 - $201,344	750 New	750 $200,000
Q1 2022 May 06, 2022	SELL	$193.77 - $244.14 $182,143 - $229,491	-940 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$223.92 - $287.77 $106,362 - $136,690	-475 Reduced 33.57%	940 $226,000
Q3 2021 Nov 05, 2021	SELL	$282.99 - $369.05 $59,427 - $77,500	-210 Reduced 12.92%	1,415 $400,000
Q2 2021 Jul 30, 2021	SELL	$259.0 - $414.71 $12,950 - $20,735	-50 Reduced 2.99%	1,625 $563,000
Q1 2021 May 05, 2021	BUY	$242.95 - $284.63 $9,718 - $11,385	40 Added 2.45%	1,675 $469,000
Q4 2020 Feb 08, 2021	BUY	$236.26 - $355.63 $34,257 - $51,566	145 Added 9.73%	1,635 $400,000
Q3 2020 Oct 22, 2020	BUY	$264.77 - $305.71 $394,507 - $455,507	1,490 New	1,490 $423,000

990

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Kendall Capital Management, based on Form 13F filings with the SEC.

Stay updated on Kendall Capital Management with notifications on news.